At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin ...

Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...

Image Credit: Newcells Biotech A two-dimensional in vitro model of retinal pigment epithelial cells derived from human induced pluripotent stem cells that replicate the phagocytosis of outer ...

Ocular complications in Thalassemia Major are often overlooked, yet early detection through regular eye exams is vital for ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Retinal degeneration is a leading cause of blindness globally and results from irreversible damage to photoreceptors and supporting cells including retinal pigment epithelium (RPE). Scientists have ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic ...

Unlike humans, embryonic chicks demonstrate a remarkable ability to regenerate their neural retina by activating neural progenitors of the ciliary margin (CM) and through retinal pigment epithelium ...

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a ...

Friday unveiled preclinical findings at the ARVO conference demonstrating that its oral candidate zervimesine protects retinal pigment epithelial cells in dry age-related macular degeneration.